Project Grant R13EB040108
- The National Institute of Biomedical Imaging and Bioengineering awarded the Regents of the University of Minnesota $209,940 on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a portable phase-only parallel transmission interface for enhancing phosphorus-31 magnetic resonance spectroscopy imaging at 7 Tesla. The recipient will design and build a digital-controlled, RF broadband interface that adjusts...
- The National Science Foundation Division of Electrical, Communications and Cyber Systems awarded Lehigh University $250,000 on July 15, 2026, under the Engineering program (CFDA 47.041) to develop a noninvasive electromagnetic method for detecting brain activity in deep brain regions. The project will demonstrate the feasibility of using electromagnetic radiation at radio or microwave wavelengths to detect activity-dependent changes in brain tissue dielectric properties, addressing an unmet need...
- The National Institute of Biomedical Imaging and Bioengineering awarded The University of Texas Southwestern Medical Center $536,853 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds development and validation of a comprehensive 7 Tesla MRI framework for simultaneous high-resolution mapping of brain iron and myelin in mesoscale brain structures. The project integrates three complementary...
- The National Science Foundation Directorate for Mathematical and Physical Sciences awarded the University of Maryland, College Park $195,997 on April 1, 2026, to support a workshop on quantum biotechnology designed to bridge innovation and impact in the field. The workshop will convene approximately 200 scientific leaders from the United States, Europe, and Australia to discuss advances in quantum technologies and identify the biomedical community's needs for improved sensing, reporting,...
- The National Science Foundation Division of Electrical, Communications and Cyber Systems awarded Arizona State University $575,942 on July 1, 2026, under the NSF Engineering program (CFDA 47.041) to develop automated full-duplex radiofrequency technology for next-generation magnetic resonance imaging systems. The project, operating through August 2026 to June 2031, aims to reduce MRI scanner size and power requirements, making imaging systems more portable and affordable for resource-limited...
- This National Science Foundation (NSF) Project Grant award to New York University (NYU) under the Computer and Information Science and Engineering program (CFDA 47.070) aims to develop an advanced software tool that automates the design and optimization of electromagnetic (EM) systems, with a focus on improving the performance of magnetic resonance imaging (MRI) devices. The $1,164,641 award, effective from August 1, 2023 to July 31, 2026, will create a software pipeline that combines geometry...
- The National Institute of Biomedical Imaging and Bioengineering awarded Northeastern University $219,818 on April 27, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a fully integrated electro-optic sensor for real-time MRI-guided interventions. The award funds development of an interventional device sensor that addresses safety and imaging limitations in MRI-guided procedures. Current active devices for...
- The National Science Foundation Division of Electrical, Communications and Cyber Systems awarded Texas Tech University $500,000 on June 1, 2026, under the Engineering program (CFDA 47.041) to develop flexible, room-temperature wearable brain-imaging sensors based on magnetic sensing technology that conform to the scalp and enable real-time neural activity measurement during natural behavior and movement. The project, titled FLEX-MEG (Flexible Quantum Magnetoencephalography), will design...
- The National Heart, Lung, and Blood Institute awarded Colorado State University $1.892 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate electrical impedance tomography (EIT) as a noninvasive functional imaging technique for assessing respiratory function in patients with muscular dystrophy, with performance through June 30, 2030, at Fort Collins, Colorado. The award funds longitudinal study of EIT effectiveness as a measure...
- The National Institute of Biomedical Imaging and Bioengineering awarded the Regents of the University of Michigan $149,264 on March 26, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop magnetic resonance fingerprinting (MRF) technology for myocardial tissue characterization in patients with cardiac implantable electronic devices. The project addresses the clinical underutilization of cardiac MRI in CIED...
2026 JOINT WORKSHOP ON MR PHASE, MAGNETIC SUSCEPTIBILITY AND ELECTRICAL PROPERTIES MAPPING - PROJECT SUMMARY WE PROPOSE TO HOLD THE 2026 JOINT WORKSHOP ON MR PHASE, MAGNETIC SUSCEPTIBILITY AND ELECTRICAL PROPERTIES (EMTP WORKSHOP) ON SEPTEMBER 20-23, 2026, IN ANNAPOLIS, MARYLAND, UNITED STATES. THE PURPOSE OF THIS MEETING IS TO CONVENE RESEARCHERS, CLINICIANS, TRAINEES, AND INDUSTRY PARTNERS WORKING ON MRI TECHNIQUES THAT MEASURE KEY ELECTROMAGNETIC TISSUE PROPERTIES, INCLUDING QUANTITATIVE SUSCEPTIBILITY MAPPING (QSM), ELECTRICAL PROPERTIES TOMOGRAPHY (EPT), AND RELATED METHODS. PARTICIPANTS WILL REVIEW RECENT PROGRESS AND IDENTIFY UNMET NEEDS FOR FUTURE DEVELOPMENT, WITH A PARTICULAR FOCUS ON FACILITATING BROADER CLINICAL ADOPTION. TISSUE ELECTROMAGNETIC PROPERTIES-MAGNETIC SUSCEPTIBILITY MEASURED BY QSM AND ELECTRICAL CONDUCTIVITY AND PERMITTIVITY MEASURED BY EPT-PROVIDE UNIQUE INFORMATION ABOUT TISSUE COMPOSITION AND MICROSTRUCTURE. THESE MEASUREMENTS OFFER QUANTITATIVE IMAGING BIOMARKERS FOR IRON AND MYELIN CONTENT, WATER CONTENT, ION CONCENTRATION, AND CELLULAR ARCHITECTURE. SUCH BIOMARKERS HAVE SHOWN DIAGNOSTIC AND PROGNOSTIC POTENTIAL ACROSS MULTIPLE NEUROLOGICAL AND SYSTEMIC DISEASES, INCLUDING MULTIPLE SCLEROSIS, PARKINSON'S DISEASE, ALZHEIMER'S DISEASE, STROKE, AND TUMORS. BUILDING ON PREVIOUS EMTP WORKSHOPS AND RECENT COMMUNITY EFFORTS TO STRENGTHEN REPRODUCIBILITY, STANDARDIZATION, AND DATA SHARING-INCLUDING CONSENSUS PAPERS AND GUIDELINES FOR QSM AND EPT-THERE IS A PRESSING NEED TO FURTHER SOLIDIFY RESEARCH AND DEVELOPMENT EFFORTS THAT SUPPORT THEIR CLINICAL TRANSLATION. STRUCTURED DIALOGUE AMONG RESEARCHERS, CLINICIANS, AND INDUSTRY PARTNERS IS ESSENTIAL FOR IDENTIFYING UNMET NEEDS AND DRIVING COORDINATED SOLUTIONS. THE WORKSHOP HAS THE FOLLOWING THREE AIMS: (1) BRING TOGETHER RESEARCHERS, CLINICIANS, AND INDUSTRY PARTNERS TO HIGHLIGHT ADVANCES, IDENTIFY KEY QUESTIONS, KNOWLEDGE GAPS, AND OBSTACLES TO THE WIDER CLINICAL ADOPTION OF QSM AND EPT; (2) FOSTER A MULTI-CENTER COLLABORATIVE WORKFORCE TO ADVANCE STANDARDIZATION, HARMONIZATION, DATA SHARING, AND BENCHMARKING ESSENTIAL FOR QUANTITATIVE IMAGING BIOMARKERS; (3) EDUCATE TRAINEES AND EARLY-CAREER INVESTIGATORS, AS WELL AS RESEARCHERS FROM DIFFERENT BACKGROUNDS ON THE FUNDAMENTALS AND STATE-OF-THE-ART DEVELOPMENTS IN QSM AND EPT. THE ORGANIZING AND STEERING COMMITTEES CONSIST OF LEADING EXPERTS IN MR PHASE, QSM, AND EPT, INCLUDING MR PHYSICISTS AND ENGINEERS, APPLIED MATHEMATICIANS, BIOLOGISTS, AND CLINICIANS, WITH REPRESENTATIONS OF BOTH JUNIOR AND SENIOR INVESTIGATORS. SCIENTIFIC PRESENTATIONS WILL BE COMBINED WITH DEDICATED PANEL AND ROUNDTABLE DISCUSSIONS TO ENABLE IN-DEPTH EXCHANGE OF IDEAS, CROSS-DISCIPLINARY BRAINSTORMING, AND ACTIVE ENGAGEMENT ACROSS THE STUDY GROUP. MULTIPLE NETWORKING OPPORTUNITIES WILL ALSO BE INCORPORATED. INFORMATION ABOUT DISABILITY ACCESS, CHILDCARE AND OTHER FAMILY CARE FACILITIES WILL BE MADE AVAILABLE TO THE ATTENDEES. THE 2026 EMTP WORKSHOP WILL BE A TIMELY EVENT TO FACILITATE EDUCATION, INTEGRATE ONGOING COMMUNITY INITIATIVES, CATALYZE NEW COLLABORATIONS, AND ACCELERATE SCIENTIFIC PROGRESS AND CLINICAL TRANSLATION OF QSM, EPT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $10.0k | 7/31/26 |